$9.38
1.88% yesterday
Nasdaq, Jun 30, 10:16 pm CET
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Intellia Therapeutics, Inc. Stock price

$9.38
+2.51 36.54% 1M
-2.03 17.79% 6M
-2.28 19.55% YTD
-13.09 58.26% 1Y
-42.38 81.88% 3Y
-11.64 55.38% 5Y
-12.72 57.56% 10Y
-12.72 57.56% 20Y
Nasdaq, Closing price Mon, Jun 30 2025
-0.18 1.88%
ISIN
US45826J1051
Symbol
NTLA
Sector
Industry

Key metrics

Basic
Market capitalization
$990.3m
Enterprise Value
$486.5m
Net debt
positive
Cash
$503.8m
Shares outstanding
103.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
21.73 | 17.17
EV/Sales
10.68 | 8.43
EV/FCF
negative
P/B
1.27
Financial Health
Equity Ratio
73.21%
Return on Equity
-59.52%
ROCE
-61.94%
ROIC
-
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$45.6m | $57.7m
EBITDA
$-530.8m | $-458.8m
EBIT
$-541.1m
Net Income
$-525.9m | $-444.3m
Free Cash Flow
$-381.2m
Growth (TTM | estimate)
Revenue
-49.81% | -0.33%
EBITDA
39.91% | 12.43%
EBIT
39.39%
Net Income
36.98% | 14.39%
Free Cash Flow
8.83%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,164.82% | -795.36%
EBIT
-1,187.36%
Net
-1,154.10% | -770.19%
Free Cash Flow
-836.43%
More
EPS
$-5.08
FCF per Share
$-3.68
Short interest
32.63%
Employees
403.00
Rev per Employee
$140.00k
Show more

Is Intellia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Intellia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Intellia Therapeutics, Inc. forecast:

26x Buy
76%
7x Hold
21%
1x Sell
3%

Analyst Opinions

34 Analysts have issued a Intellia Therapeutics, Inc. forecast:

Buy
76%
Hold
21%
Sell
3%

Financial data from Intellia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
46 46
50% 50%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 124 124
40% 40%
272%
- Research and Development Expense 463 463
40% 40%
1,016%
-531 -531
40% 40%
-1,165%
- Depreciation and Amortization 10 10
9% 9%
23%
EBIT (Operating Income) EBIT -541 -541
39% 39%
-1,187%
Net Profit -526 -526
37% 37%
-1,154%

In millions USD.

Don't miss a Thing! We will send you all news about Intellia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Intellia Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
15 days ago
CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also kn...
Neutral
GlobeNewsWire
25 days ago
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.
Negative
MarketBeat
about one month ago
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
More Intellia Therapeutics, Inc. News

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO John Leonard
Employees 403
Founded 2014
Website www.intelliatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today